<![CDATA[Bavarian Nordic — Februar 2019]]>Pharm-Olam Enrolls Patients in Zealand Pharma Orphan Drug Study (SBS)

(February 05, 2019 08:05 AM Eastern Standard Time)

https://www.businesswire.com/news/home/20190205005137/en/Pharm-Olam-Enrolls-Patients-Zealand-Pharma-Orphan-Drug

]]>https://dev.proinvestor.com/forum/topic/451956/bavarian-nordic-februar-2019RSS for NodeSat, 13 Jun 2026 15:10:52 GMTWed, 06 Feb 2019 06:26:58 GMT60<![CDATA[Reply to Bavarian Nordic — Februar 2019 on Tue, 26 Feb 2019 17:12:11 GMT]]>Ny CEO, partneraftale eller salg af hele butikken, hvad mon fremtiden bringer?!

]]>https://dev.proinvestor.com/forum/post/10491489https://dev.proinvestor.com/forum/post/10491489Tue, 26 Feb 2019 17:12:11 GMT<![CDATA[Reply to Bavarian Nordic — Februar 2019 on Tue, 26 Feb 2019 17:04:27 GMT]]>Biotekchef på vej til udlandet stopper i dansk bestyrelsesjob

Britt Meelby Jensen, der kun har få dage tilbage som topchef i Zealand Pharma, forlader nu også diagnostikselskabet Bioporto, hvor hun siden foråret sidste år har siddet i bestyrelsen sammen med blandt andre Symphogen-stifteren Kirsten Drejer.

Link Preview Image
Biotekchef på vej til udlandet stopper i dansk bestyrelsesjob

Britt Meelby Jensen, der kun har få dage tilbage som topchef i Zealand Pharma, forlader nu også diagnostikselskabet Bioporto, hvor hun siden foråret sidste år har siddet i bestyrelsen sammen med blandt andre Symphogen-stifteren Kirsten Drejer.

favicon

Finans (finans.dk)

]]>https://dev.proinvestor.com/forum/post/10491486https://dev.proinvestor.com/forum/post/10491486Tue, 26 Feb 2019 17:04:27 GMT<![CDATA[Reply to Bavarian Nordic — Februar 2019 on Fri, 22 Feb 2019 12:52:40 GMT]]>... hvor de helt store spillere (Pfizer, GSK, Johnson & Johnson, NIH) er på vej frem med nyere RSV vaccinesammensætning end Bavarians lidt gammeldags. Med alle de konkurrenter er det næsten svært at se, hvem der vil være partneraftager på RSV.

]]>https://dev.proinvestor.com/forum/post/10491490https://dev.proinvestor.com/forum/post/10491490Fri, 22 Feb 2019 12:52:40 GMT<![CDATA[Reply to Bavarian Nordic — Februar 2019 on Fri, 22 Feb 2019 12:47:10 GMT]]>Ingen tvivl om, at de har de-risket nyhedsflowet og pipelinen med deres aflysning af RSV human challenge og aflysning af de ekstra selvfinansierede CV301 projekter. Det kommer til at ligne et nyhedsflow med neutrale (opstart af X forsøg) og positive nyheder (FDA godkendelse af Imvamune) henover året med kun meget få relativt begrænsede negative triggere (såsom dårlige brachyury/CV301 resultater). Den store trigger er evt. partnerskab på RSV, som p.t. er et område.....

]]>https://dev.proinvestor.com/forum/post/10491488https://dev.proinvestor.com/forum/post/10491488Fri, 22 Feb 2019 12:47:10 GMT<![CDATA[Reply to Bavarian Nordic — Februar 2019 on Fri, 22 Feb 2019 10:47:04 GMT]]>Så har købt ekstra op til pensionsporteføljen (meget lang). Den kommer ikke til at kunne fåes i nærheden af nuværende kurs om 1 år.

]]>https://dev.proinvestor.com/forum/post/10491482https://dev.proinvestor.com/forum/post/10491482Fri, 22 Feb 2019 10:47:04 GMT<![CDATA[Reply to Bavarian Nordic — Februar 2019 on Fri, 22 Feb 2019 10:46:11 GMT]]>I øvrigt tror jeg vi vil se et fint nyheds-/forsøgsdata-momentum bygge op i løbet af 19, så er meget positiv på BAVA lige nu. De har en virusbaseret leveringsteknologi, der virkelig kan noget særligt. Flere meget interessante stoffer. Om godt 1 år har de osse en stor og hyper moderne fabrikationsfacilitet (betalt af den amerikanske regering... ref. Trump, der ville have Mexico til at betale for muren. Hi hi...), som formentlig ikke findes mage mange steder.

]]>https://dev.proinvestor.com/forum/post/10491483https://dev.proinvestor.com/forum/post/10491483Fri, 22 Feb 2019 10:46:11 GMT<![CDATA[Reply to Bavarian Nordic — Februar 2019 on Fri, 22 Feb 2019 10:31:41 GMT]]>Sent på den... tjo, tja, et par måneder fra eller til... i biotek-klinik-tidsskala.. er vist at puste en fjer op til 5 høns på taget.. 😉

]]>https://dev.proinvestor.com/forum/post/10491487https://dev.proinvestor.com/forum/post/10491487Fri, 22 Feb 2019 10:31:41 GMT<![CDATA[Reply to Bavarian Nordic — Februar 2019 on Fri, 22 Feb 2019 08:11:36 GMT]]>Opstart i H2 2018: http://www.bavarian-nordic.com/media/273834/2018-q3-en.pdf

]]>https://dev.proinvestor.com/forum/post/10491481https://dev.proinvestor.com/forum/post/10491481Fri, 22 Feb 2019 08:11:36 GMT<![CDATA[Reply to Bavarian Nordic — Februar 2019 on Fri, 22 Feb 2019 08:10:05 GMT]]>Javel - og hvad er det de tidligere har meldt ud om timeframe...?

]]>https://dev.proinvestor.com/forum/post/10491485https://dev.proinvestor.com/forum/post/10491485Fri, 22 Feb 2019 08:10:05 GMT<![CDATA[Reply to Bavarian Nordic — Februar 2019 on Fri, 22 Feb 2019 08:07:12 GMT]]>HPV samarbejdet med Janssen er ikke en nyhed. De er faktisk sent på den, ud fra hvad der tidligere er blevet meldt ud, så man kan sige, at det er fint, at de kom i gang.

]]>https://dev.proinvestor.com/forum/post/10491479https://dev.proinvestor.com/forum/post/10491479Fri, 22 Feb 2019 08:07:12 GMT<![CDATA[Reply to Bavarian Nordic — Februar 2019 on Thu, 21 Feb 2019 21:34:52 GMT]]>
ClinicalTrials.gov

favicon

(clinicaltrials.gov)

]]>https://dev.proinvestor.com/forum/post/10491478https://dev.proinvestor.com/forum/post/10491478Thu, 21 Feb 2019 21:34:52 GMT<![CDATA[Reply to Bavarian Nordic — Februar 2019 on Thu, 21 Feb 2019 21:34:28 GMT]]>Stort marked hvis de lykkes! Forsøget har Primary Completion Date: August 9, 2020, så lidt tid endnu tager det da...

]]>https://dev.proinvestor.com/forum/post/10491476https://dev.proinvestor.com/forum/post/10491476Thu, 21 Feb 2019 21:34:28 GMT<![CDATA[Reply to Bavarian Nordic — Februar 2019 on Thu, 21 Feb 2019 21:32:49 GMT]]>

favicon

(www.bavarian-nordic.com)

]]>https://dev.proinvestor.com/forum/post/10491484https://dev.proinvestor.com/forum/post/10491484Thu, 21 Feb 2019 21:32:49 GMT<![CDATA[Reply to Bavarian Nordic — Februar 2019 on Thu, 21 Feb 2019 21:32:33 GMT]]>to precancerous cell changes. It is estimated, that high-risk HPV types cause approximately 5 percent of all cancers worldwide.

]]>https://dev.proinvestor.com/forum/post/10491477https://dev.proinvestor.com/forum/post/10491477Thu, 21 Feb 2019 21:32:33 GMT<![CDATA[Reply to Bavarian Nordic — Februar 2019 on Thu, 21 Feb 2019 21:32:29 GMT]]>With over 300 million estimated infections among men and women annually, HPV (human papillomavirus) is the most prevalent sexually transmitted disease in the world.

HPV is the primary cause of cervical cancer and certain types of head and neck cancer, in addition to a number of more rare cancers. Although vaccines have become available to protect against various high-risk HPV subtypes that can cause cancer, there is an unmet need for a therapeutic approach for chronic infections that may lead

]]>https://dev.proinvestor.com/forum/post/10491474https://dev.proinvestor.com/forum/post/10491474Thu, 21 Feb 2019 21:32:29 GMT<![CDATA[Reply to Bavarian Nordic — Februar 2019 on Thu, 21 Feb 2019 21:31:07 GMT]]>MVA-BN HPV is a new vaccine candidate, designed for Janssen as part of the development of a prime-boost vaccine regimen with Janssen’s AdVac technology. The prime-boost vaccine is targeting HPV and represents a novel approach for early treatment and interception of HPV-induced cancers The long-term goal is to develop a vaccine to treat chronic HPV infections as well as prevent precancerous stages of HPV-induced cancer.

]]>https://dev.proinvestor.com/forum/post/10491470https://dev.proinvestor.com/forum/post/10491470Thu, 21 Feb 2019 21:31:07 GMT<![CDATA[Reply to Bavarian Nordic — Februar 2019 on Thu, 21 Feb 2019 21:28:39 GMT]]>
Link Preview Image
News | Bavarian Nordic

Bavarian Nordic - a pioneering force in vaccines – expanding our reach and impact through life-changing solutions

favicon

(www.bavarian-nordic.com)

]]>https://dev.proinvestor.com/forum/post/10491468https://dev.proinvestor.com/forum/post/10491468Thu, 21 Feb 2019 21:28:39 GMT<![CDATA[Reply to Bavarian Nordic — Februar 2019 on Thu, 21 Feb 2019 21:28:35 GMT]]>startes op i PhI/II...

]]>https://dev.proinvestor.com/forum/post/10491480https://dev.proinvestor.com/forum/post/10491480Thu, 21 Feb 2019 21:28:35 GMT<![CDATA[Reply to Bavarian Nordic — Februar 2019 on Thu, 21 Feb 2019 21:27:26 GMT]]>Bavarian Nordic Announces Initiation of Phase 1/2a Clinical Trial of Therapeutic HPV Vaccine Regimen in Collaboration with Janssen.

]]>https://dev.proinvestor.com/forum/post/10491473https://dev.proinvestor.com/forum/post/10491473Thu, 21 Feb 2019 21:27:26 GMT<![CDATA[Reply to Bavarian Nordic — Februar 2019 on Thu, 21 Feb 2019 21:27:09 GMT]]>YESS! Endnu en vaccine med Jansen

]]>https://dev.proinvestor.com/forum/post/10491469https://dev.proinvestor.com/forum/post/10491469Thu, 21 Feb 2019 21:27:09 GMT<![CDATA[Reply to Bavarian Nordic — Februar 2019 on Thu, 21 Feb 2019 10:43:30 GMT]]>Der må da snart komme nyt mht. den nye CEO eller fx en partneraftale på Dasiglucagon ready-to-use superior rescue pennen.

]]>https://dev.proinvestor.com/forum/post/10491472https://dev.proinvestor.com/forum/post/10491472Thu, 21 Feb 2019 10:43:30 GMT<![CDATA[Reply to Bavarian Nordic — Februar 2019 on Wed, 13 Feb 2019 10:06:49 GMT]]>Ny analyse video:

ALK-abello,
Ambu
Bavarian
Carlsberg

Just a moment...

favicon

(www.proinvestor.com)

]]>https://dev.proinvestor.com/forum/post/10491467https://dev.proinvestor.com/forum/post/10491467Wed, 13 Feb 2019 10:06:49 GMT<![CDATA[Reply to Bavarian Nordic — Februar 2019 on Thu, 07 Feb 2019 14:22:43 GMT]]>Sanofi oplyser at Zealand Pharma's tidligere kombinationspræparat Soliqua går frem med +188.9% i Q4 2018.

]]>https://dev.proinvestor.com/forum/post/10491471https://dev.proinvestor.com/forum/post/10491471Thu, 07 Feb 2019 14:22:43 GMT<![CDATA[Reply to Bavarian Nordic — Februar 2019 on Thu, 07 Feb 2019 13:52:54 GMT]]>På trods af at dax'en falder og er nede med omkring -2% i dag, så fortsætter Nordea ufortrødent med at købe Zealand Pharma.

]]>https://dev.proinvestor.com/forum/post/10491475https://dev.proinvestor.com/forum/post/10491475Thu, 07 Feb 2019 13:52:54 GMT